Message Font: Serif | Sans-Serif
No. of Recommendations: 1
FDA Approves Expanded Use Of Rituxan® For Treatment Of Low-Grade Non-Hodgkin's Lymphoma (NHL)

SOUTH SAN FRANCISCO and SAN DIEGO, CALIF. – May 14, 2001 – Genentech, Inc. (NYSE: DNA) and IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biological License Application (sBLA) for Rituxan® (Rituximab).

The new product labeling includes retreatment with Rituxan after a prior course of Rituxan therapy, initial treatment with eight weekly infusions of Rituxan, compared to four infusions, and treatment of bulky disease (tumors greater than 10 centimeters) for patients with relapsed or refractory, low-grade or follicular, CD20 positive B-cell non-Hodgkin's lymphoma (NHL). Additionally, the two companies will emphasize already existing safety information in the revised package insert for physicians concerning rare severe and potentially fatal mucocutaneous skin reactions that have occurred in patients who have received Rituxan.

Rest of the article here:

Foolish Regards

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.